Chaudhary, Attiqa http://orcid.org/0000-0003-2446-7791
Abbott, Carla J. http://orcid.org/0000-0002-1432-8977
Wu, Zhichao http://orcid.org/0000-0002-8623-6684
Fang, Wendy Y. http://orcid.org/0000-0002-9004-4773
Raj, Palaniraj R. http://orcid.org/0000-0002-9018-0644
Naughton, Matthew T. http://orcid.org/0000-0003-2734-0841
Guymer, Robyn H. http://orcid.org/0000-0002-9441-4356
Funding for this research was provided by:
National Health and Medical Research Council (GNT1181010)
National Health and Medical Research Council (1194667)
University of Melbourne
Article History
Received: 22 September 2023
Revised: 8 February 2024
Accepted: 28 February 2024
First Online: 19 March 2024
Declarations
:
: ClinicalTrials.gov Identifier NCT04739319; Royal Victorian Eye and Ear Hospital Human Research Ethics Committee approval (20/149H).
: RHG is an advisory board member of Roche, Genentech, Bayer, Novartis, Apellis outside the submitted work. Other authors report no conflict of interest.